Drug Type Biological products |
Synonyms |
Target |
Mechanism IL-18 inhibitors(Interleukin 18 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 2 | HU | 20 Apr 2021 | |
Dermatitis, Atopic | Phase 2 | ES | 20 Apr 2021 | |
Dermatitis, Atopic | Phase 2 | FR | 20 Apr 2021 | |
Dermatitis, Atopic | Phase 2 | PL | 20 Apr 2021 | |
Sarcoidosis, Pulmonary | Phase 2 | US | 23 Sep 2020 | |
Sarcoidosis, Pulmonary | Phase 2 | GB | 23 Sep 2020 | |
Sarcoidosis, Pulmonary | Phase 2 | CZ | 23 Sep 2020 | |
Sarcoidosis, Pulmonary | Phase 2 | DK | 23 Sep 2020 | |
Sarcoidosis, Pulmonary | Phase 2 | PL | 23 Sep 2020 | |
Sarcoidosis, Pulmonary | Phase 2 | DE | 23 Sep 2020 |
Phase 2 | 71 | (CMK389 10mg/kg i.v.) | qshvaowuum(opdprplyrd) = ttamzetehc hdemzoluei (cnekhsbemh, oeakjjweuu - pnpzrjvmoy) View more | - | 09 May 2024 | ||
(CMK389 300mg s.c.) | qshvaowuum(opdprplyrd) = sxxsqjzyvb hdemzoluei (cnekhsbemh, zeaspryfdw - uctvkqvncv) View more |